JP2022516555A5 - - Google Patents

Info

Publication number
JP2022516555A5
JP2022516555A5 JP2021538976A JP2021538976A JP2022516555A5 JP 2022516555 A5 JP2022516555 A5 JP 2022516555A5 JP 2021538976 A JP2021538976 A JP 2021538976A JP 2021538976 A JP2021538976 A JP 2021538976A JP 2022516555 A5 JP2022516555 A5 JP 2022516555A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
membered
aryl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012260 external-priority patent/WO2020142742A1/en
Publication of JP2022516555A publication Critical patent/JP2022516555A/ja
Publication of JP2022516555A5 publication Critical patent/JP2022516555A5/ja
Pending legal-status Critical Current

Links

JP2021538976A 2019-01-04 2020-01-03 線維芽細胞活性化タンパク質の阻害剤 Pending JP2022516555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788722P 2019-01-04 2019-01-04
US62/788,722 2019-01-04
US201962863853P 2019-06-19 2019-06-19
US62/863,853 2019-06-19
PCT/US2020/012260 WO2020142742A1 (en) 2019-01-04 2020-01-03 Inhibitors of fibroblast activation protein

Publications (2)

Publication Number Publication Date
JP2022516555A JP2022516555A (ja) 2022-02-28
JP2022516555A5 true JP2022516555A5 (https=) 2023-01-11

Family

ID=71404153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538976A Pending JP2022516555A (ja) 2019-01-04 2020-01-03 線維芽細胞活性化タンパク質の阻害剤

Country Status (13)

Country Link
US (1) US20200216417A1 (https=)
EP (1) EP3906024A4 (https=)
JP (1) JP2022516555A (https=)
KR (1) KR20210113634A (https=)
CN (1) CN114126597A (https=)
AU (1) AU2020204714A1 (https=)
BR (1) BR112021011861A2 (https=)
CA (1) CA3124525A1 (https=)
CL (1) CL2021001739A1 (https=)
IL (1) IL284434A (https=)
MX (1) MX2021007948A (https=)
SG (1) SG11202106399XA (https=)
WO (1) WO2020142742A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US11780821B2 (en) 2017-12-15 2023-10-10 Praxis Biotech LLC Inhibitors of fibroblast activation protein
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11504364B2 (en) 2018-12-21 2022-11-22 Praxis Biotech LLC Inhibitors of fibroblast activation protein
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
BR112021025637A2 (pt) 2019-06-19 2022-02-01 Nmd Pharma As Compostos para o tratamento de doenças neuromusculares
EP4096677A4 (en) * 2020-01-31 2024-02-28 Purdue Research Foundation Fibroblast activation protein (fap) - targeted antifibrotic therapy
CN115819443B (zh) * 2022-08-02 2025-03-21 中国科学院上海应用物理研究所 一种含烯基化合物及其应用
WO2025159534A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 3-스티릴피리딘 구조 기반의 섬유아세포 활성화 단백질 표적 물질
CN118978511A (zh) * 2024-08-02 2024-11-19 江苏华益科技有限公司 一种靶向fap化合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399869B2 (en) * 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
CA2617715A1 (en) * 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
WO2013107820A1 (en) * 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
US11780821B2 (en) * 2017-12-15 2023-10-10 Praxis Biotech LLC Inhibitors of fibroblast activation protein
US11504364B2 (en) * 2018-12-21 2022-11-22 Praxis Biotech LLC Inhibitors of fibroblast activation protein

Similar Documents

Publication Publication Date Title
JP2022516555A5 (https=)
JP2022514352A5 (https=)
IL275333B2 (en) Inhibitors of fibroblast activation protein
KR102709127B1 (ko) Fak 억제제 및 그 약물 조합물
EP1339458B1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
RU2008136188A (ru) Противораковая фармацевтическая композиция
JP2007501238A (ja) 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用
JP2024524373A5 (https=)
RU2008115454A (ru) Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
JP2003523381A (ja) 投与レジメン
ZA200307665B (en) Combination comprising N-{5-[4-(4-methyl-piperazinomethyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent.
KR20210095721A (ko) 인돌리논 화합물의 용도
JP2021514395A5 (https=)
KR102748684B1 (ko) 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법
JP2023509359A5 (https=)
CA2496688A1 (en) Glycinamide derivatives as raf-kinase inhibitors
JP2003525239A (ja) タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
WO2022092085A1 (ja) 腫瘍治療用医薬組成物
RU2007126746A (ru) Новые производные гидантоина в качестве ингибиторов металлопротеиназ
JP2005515967A5 (https=)
WO2020187188A1 (zh) 喹啉衍生物及免疫调节剂联合在制备抗肿瘤药物中的应用
TW202102216A (zh) 抗腫瘤組合物
JP2008527039A5 (https=)
RU2021121980A (ru) Ингибиторы белка активации фибробластов